Envestnet Portfolio Solutions Inc. Has $13.56 Million Stock Holdings in Merck & Co., Inc. $MRK

Key Points

• Envestnet Portfolio Solutions increased its Merck stake by 28.3% in the second quarter, bringing its holdings to 105,500 shares valued at approximately $13.56 million. Institutional investors and hedge funds collectively own 76.07% of Merck.
• Merck reported quarterly revenue of $16.61 billion, above estimates, while earnings exceeded consensus expectations; revenue rose 5.1% year over year. The company also declared a quarterly dividend of $0.85 per share, representing a 2.3% yield.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $154.24, supported by potential oncology pipeline catalysts and recent product-label expansions. However, insiders sold about $30 million of stock over the past 90 days, and valuation and portfolio-renewal risks remain concerns.

Envestnet Portfolio Solutions Inc. boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 28.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 105,500 shares of the company's stock after purchasing an additional 23,240 shares during the quarter. Envestnet Portfolio Solutions Inc.'s holdings in Merck & Co., Inc. were worth $13,557,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. BlackRock Inc. increased its stake in shares of Merck & Co., Inc. by 0.5% during the second quarter. BlackRock Inc. now owns 226,999,837 shares of the company's stock worth $29,169,479,000 after purchasing an additional 1,073,507 shares during the period. State Street Corp increased its position in Merck & Co., Inc. by 0.9% during the second quarter. State Street Corp now owns 120,413,256 shares of the company's stock worth $15,573,754,000 after acquiring an additional 1,087,583 shares during the period. Wellington Management Group LLP grew its position in shares of Merck & Co., Inc. by 2.3% during the 2nd quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company's stock worth $11,083,033,000 after purchasing an additional 1,934,312 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Merck & Co., Inc. by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company's stock worth $6,307,572,000 after purchasing an additional 249,110 shares during the period. Finally, Norges Bank acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $3,997,933,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Merck & Co., Inc. Stock Down 1.9%

Shares of NYSE:MRK opened at $148.07 on Thursday. The company has a debt-to-equity ratio of 1.22, a quick ratio of 1.10 and a current ratio of 1.32. Merck & Co., Inc. has a 52-week low of $77.58 and a 52-week high of $156.92. The company has a market capitalization of $365.31 billion, a PE ratio of 118.46, a price-to-earnings-growth ratio of 6.57 and a beta of 0.21. The company has a fifty day moving average of $140.06 and a 200-day moving average of $125.88.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The business's quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the company earned $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. On average, equities analysts predict that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.3%. Merck & Co., Inc.'s payout ratio is currently 272.00%.

Insiders Place Their Bets

In related news, EVP David Williams sold 52,847 shares of the firm's stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares of the company's stock, valued at $4,084,069.32. This trade represents a 62.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the transaction, the executive vice president directly owned 36,613 shares in the company, valued at $4,942,755. The trade was a 21.45% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 over the last ninety days. 0.17% of the stock is currently owned by corporate insiders.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Pipeline catalysts could support a re-rating. Bank of America maintained a Buy rating, citing confidence from Merck’s chief medical officer and multiple potential oncology and other pipeline readouts expected over the next 12 to 18 months. Merck pipeline seen driving potential re-rating as clinical catalysts approach
• Positive Sentiment: WINREVAIR received a U.S. label expansion. The FDA approved an update incorporating Phase 3 HYPERION trial data for recently diagnosed adults with pulmonary arterial hypertension. The broader label may expand the therapy’s commercial opportunity and strengthen Merck’s growth portfolio. FDA approves WINREVAIR label update
• Positive Sentiment: Merck gained another KEYTRUDA administration option in Japan. Japanese approval of subcutaneous KEYTRUDA QLEX provides an alternative to intravenous dosing across existing indications and could improve convenience for patients and clinicians. Why Merck is in focus after Japan cleared a new dosing option
• Neutral Sentiment: Analyst coverage remains broadly favorable, with the average brokerage recommendation equivalent to Buy. However, the usefulness of consensus ratings may be limited because sell-side recommendations can be overly optimistic. Wall Street analysts think Merck is a good investment
• Negative Sentiment: Profit-taking and valuation concerns pressured the stock. After rising sharply over the past year and reaching elevated valuation levels, one analysis warned that the recent “melt-up” could lead to further profit-taking and assigned a more cautious rating tied to the risks of Merck’s longer-term portfolio renewal. Merck’s melt-up triggers profit-taking risks

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MRK. Leerink Partners increased their price target on Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an "outperform" rating in a research report on Wednesday, September 9th. UBS Group lifted their price objective on Merck & Co., Inc. from $145.00 to $175.00 and gave the company a "buy" rating in a report on Thursday, August 20th. Barclays upped their target price on Merck & Co., Inc. from $140.00 to $150.00 and gave the company an "overweight" rating in a research report on Wednesday, July 29th. The Goldman Sachs Group raised their target price on shares of Merck & Co., Inc. from $140.00 to $160.00 and gave the company a "buy" rating in a report on Friday, August 21st. Finally, Wall Street Zen raised shares of Merck & Co., Inc. from a "hold" rating to a "buy" rating in a research note on Sunday. Seventeen research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company's stock. Based on data from MarketBeat, Merck & Co., Inc. presently has an average rating of "Moderate Buy" and a consensus price target of $154.24.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures, and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets worldwide through its Human Health and Animal Health businesses.

Merck's pharmaceutical portfolio includes oncology, infectious disease, cardiology, immunology, and other therapeutic areas. Its products include Keytruda, an immunotherapy used to treat various cancers; Gardasil, a vaccine that helps protect against human papillomavirus (HPV); and Januvia, a treatment for type 2 diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.